awmsg logo



paclitaxel albumin-bound nanoparticles (Abraxane®)


Reference No. 1999

Publication date:
19/09/2014


Appraisal information

paclitaxel albumin-bound nanoparticles (Abraxane®) 5 mg/ml powder for suspension for infusion


Company: Celgene Ltd
BNF category: Malignant disease and immunosupression
NMG meeting date: 23/07/2014
AWMSG meeting date: 03/09/2014
   
   
Submission Type: Full Submission
Status: Recommended
Advice No: 2414
Ministerial ratification: 19/09/2014

Current Progress


Submission
received
NMG
meeting
AWMSG
meeting
Ministerial
Ratification

AWMSG advice

Paclitaxel albumin bound nanoparticles (Abraxane®) is recommended as an option for use within NHS Wales in combination with gemcitabine for the first-line treatment of adult patients with metastatic adenocarcinoma of the pancreas.
Final Appraisal Recommendation (FAR)
Download
AWMSG Secretariat Appraisal Report (ASAR)
Download
Clinical Expert (CE) Summary
Download